JP2013500314A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500314A5 JP2013500314A5 JP2012522195A JP2012522195A JP2013500314A5 JP 2013500314 A5 JP2013500314 A5 JP 2013500314A5 JP 2012522195 A JP2012522195 A JP 2012522195A JP 2012522195 A JP2012522195 A JP 2012522195A JP 2013500314 A5 JP2013500314 A5 JP 2013500314A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- heteroaryl
- alkyl
- ethyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 9
- -1 2- (4-fluorophenyl) ethyl Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 101100439663 Arabidopsis thaliana CHR7 gene Proteins 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000004962 physiological condition Effects 0.000 claims 2
- 238000004321 preservation Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 101100134922 Gallus gallus COR5 gene Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000003181 biological factor Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000004153 islets of langerhan Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200901757 | 2009-07-30 | ||
| ES200901757 | 2009-07-30 | ||
| PCT/ES2010/000349 WO2011012746A2 (es) | 2009-07-30 | 2010-07-29 | Compuestos inhibidores de apaf-1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013500314A JP2013500314A (ja) | 2013-01-07 |
| JP2013500314A5 true JP2013500314A5 (enExample) | 2013-09-12 |
| JP5694320B2 JP5694320B2 (ja) | 2015-04-01 |
Family
ID=43529761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522195A Expired - Fee Related JP5694320B2 (ja) | 2009-07-30 | 2010-07-29 | Ａｐａｆ−１阻害剤化合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9040701B2 (enExample) |
| EP (1) | EP2460798B1 (enExample) |
| JP (1) | JP5694320B2 (enExample) |
| KR (1) | KR101786761B1 (enExample) |
| CN (1) | CN102574818B (enExample) |
| AU (1) | AU2010277505B2 (enExample) |
| BR (1) | BR112012002134B8 (enExample) |
| CA (1) | CA2769408C (enExample) |
| EA (1) | EA021838B1 (enExample) |
| ES (1) | ES2727711T3 (enExample) |
| IN (1) | IN2012DN01378A (enExample) |
| MX (1) | MX2012001339A (enExample) |
| NZ (1) | NZ598125A (enExample) |
| TR (1) | TR201907804T4 (enExample) |
| WO (1) | WO2011012746A2 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006259415B2 (en) | 2005-06-15 | 2012-08-30 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
| RS57314B1 (sr) | 2009-12-01 | 2018-08-31 | Translate Bio Inc | Isporuka irnk za povećanje ekspresije proteina i enzima u humanim genetskim oboljenjima |
| US9193827B2 (en) | 2010-08-26 | 2015-11-24 | Massachusetts Institute Of Technology | Poly(beta-amino alcohols), their preparation, and uses thereof |
| US9238716B2 (en) | 2011-03-28 | 2016-01-19 | Massachusetts Institute Of Technology | Conjugated lipomers and uses thereof |
| LT2717893T (lt) | 2011-06-08 | 2019-08-12 | Translate Bio, Inc. | Lipidų nanodalelių kompozicijos ir mrnr pristatymo būdai |
| PE20181541A1 (es) * | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| US20150267192A1 (en) | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| ES2443538B1 (es) * | 2012-07-19 | 2014-11-26 | Consejo Superior De Investigaciones Cientificas (Csic) | Compuestos beta-lactámicos inhibidores de APAF1 |
| EP2882706A1 (en) | 2012-08-13 | 2015-06-17 | Massachusetts Institute of Technology | Amine-containing lipidoids and uses thereof |
| EP3467108B1 (en) | 2013-03-14 | 2024-05-22 | Translate Bio, Inc. | Methods for purification of messenger rna |
| MX393573B (es) | 2013-03-14 | 2025-03-21 | Shire Human Genetic Therapies | Composiciones de acido ribonucleico mensajero del regulador transmembrana de fibrosis quistica y metodos y usos relacionados |
| WO2014179562A1 (en) | 2013-05-01 | 2014-11-06 | Massachusetts Institute Of Technology | 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof |
| AU2014340092B2 (en) | 2013-10-22 | 2019-09-19 | Translate Bio, Inc. | mRNA therapy for Argininosuccinate Synthetase Deficiency |
| CN105813656B (zh) | 2013-10-22 | 2021-01-15 | 夏尔人类遗传性治疗公司 | 用于递送信使rna的脂质制剂 |
| EA201992208A1 (ru) | 2013-10-22 | 2020-07-31 | Транслейт Био, Инк. | ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК |
| DK3636742T3 (da) | 2014-04-25 | 2025-11-24 | Translate Bio Inc | Fremgangsmåder til oprensning af messenger-rna |
| EP3587409B8 (en) | 2014-05-30 | 2022-07-13 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| EA033966B1 (ru) | 2014-06-24 | 2019-12-13 | Транслейт Био, Инк. | Стереохимически обогащенные композиции для доставки нуклеиновых кислот |
| EP3164379A1 (en) | 2014-07-02 | 2017-05-10 | Massachusetts Institute of Technology | Polyamine-fatty acid derived lipidoids and uses thereof |
| CA2990172A1 (en) | 2015-06-19 | 2016-12-22 | Massachusetts Institute Of Technology | Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell |
| MX2019010155A (es) | 2017-02-27 | 2020-12-10 | Translate Bio Inc | Arnm de cftr optimizado por codón novedoso. |
| WO2018213476A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| WO2019204653A1 (en) | 2018-04-19 | 2019-10-24 | Spiral Therapeutics, Inc. | Inner ear drug delivery devices and methods of use |
| KR20210060480A (ko) | 2018-08-24 | 2021-05-26 | 트랜슬레이트 바이오 인코포레이티드 | 전령 rna의 정제 방법 |
| MX2021005969A (es) | 2018-11-21 | 2021-09-14 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado. |
| US10561736B1 (en) | 2019-01-09 | 2020-02-18 | Spiral Therapeutics, Inc. | Apoptosis inhibitor formulations for prevention of hearing loss |
| CA3131378A1 (en) | 2019-02-25 | 2020-09-03 | Spiral Therapeutics Inc. | Intratympanic injector devices and needles for delivery of drugs and methods of use |
| CA3165918A1 (en) | 2020-01-24 | 2021-07-29 | Eugene De Juan | Systems and methods for treating hearing loss |
| EP4137131A1 (en) * | 2021-08-17 | 2023-02-22 | Centre National de la Recherche Scientifique (CNRS) | Novel serotonin analogues and their uses for treating iron-associated disorders |
| CN115124449B (zh) * | 2022-05-24 | 2024-02-02 | 上海英诺富成生物科技有限公司 | 一种吲哚化合物及制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3560503A (en) * | 1968-09-18 | 1971-02-02 | Council Scient Ind Res | Di-lower alkyl-substituted octahydropyrazinopyrimidinones |
| GB1284582A (en) | 1969-11-10 | 1972-08-09 | Council Scient Ind Res | Substituted piperazinopyrimidinones |
| JPH04234375A (ja) | 1990-12-27 | 1992-08-24 | Ajinomoto Co Inc | 新規２，５−ジオキソピペラジン化合物及びその製造法 |
| HUT68769A (en) * | 1991-05-07 | 1995-07-28 | Merck & Co Inc | FIBRINOGéN RECEPTOR ANTAGONIST COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS EFFECTIVE SUBSTANCE |
| JPH05117246A (ja) | 1991-10-23 | 1993-05-14 | Ajinomoto Co Inc | 新規２，５−ジオキソピペラジン化合物とその製造法及びα−Ｌ−アスパルチル−Ｌ−フエニルアラニンメチルエステル誘導体の製造法 |
| WO1996000391A1 (en) * | 1994-06-23 | 1996-01-04 | Affymax Technologies N.V. | Methods for the synthesis of diketopiperazines |
| CA2434184A1 (en) * | 2001-01-19 | 2002-09-12 | Pharmacopeia, Inc. | Bisaryl derivatives having fsh receptor modulatory activity |
| AU2003279761B2 (en) | 2002-10-02 | 2009-11-12 | Luoxis Diagnostics, Inc. | Diagnosis and monitoring of diseases |
| WO2005052177A1 (ja) | 2003-11-28 | 2005-06-09 | Kyowa Hakko Kogyo Co., Ltd. | ジペプチドの製造法 |
| ES2296484B1 (es) * | 2005-11-23 | 2009-04-01 | Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) | Composicion farmaceutica para inhibir la apoptosis. |
| ES2293834B1 (es) * | 2006-07-20 | 2009-02-16 | Consejo Superior Investig. Cientificas | Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. |
-
2010
- 2010-07-29 IN IN1378DEN2012 patent/IN2012DN01378A/en unknown
- 2010-07-29 NZ NZ598125A patent/NZ598125A/en not_active IP Right Cessation
- 2010-07-29 CN CN201080043254.1A patent/CN102574818B/zh not_active Expired - Fee Related
- 2010-07-29 JP JP2012522195A patent/JP5694320B2/ja not_active Expired - Fee Related
- 2010-07-29 EP EP10803937.1A patent/EP2460798B1/en active Active
- 2010-07-29 TR TR2019/07804T patent/TR201907804T4/tr unknown
- 2010-07-29 ES ES10803937T patent/ES2727711T3/es active Active
- 2010-07-29 WO PCT/ES2010/000349 patent/WO2011012746A2/es not_active Ceased
- 2010-07-29 BR BR112012002134A patent/BR112012002134B8/pt not_active IP Right Cessation
- 2010-07-29 CA CA2769408A patent/CA2769408C/en active Active
- 2010-07-29 KR KR1020127005131A patent/KR101786761B1/ko not_active Expired - Fee Related
- 2010-07-29 EA EA201270215A patent/EA021838B1/ru not_active IP Right Cessation
- 2010-07-29 MX MX2012001339A patent/MX2012001339A/es active IP Right Grant
- 2010-07-29 AU AU2010277505A patent/AU2010277505B2/en not_active Ceased
- 2010-07-29 US US13/387,240 patent/US9040701B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500314A5 (enExample) | ||
| JP2019517487A5 (enExample) | ||
| JP2018507890A5 (enExample) | ||
| JP2016531126A5 (enExample) | ||
| JP2015500843A5 (enExample) | ||
| RU2350605C2 (ru) | Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2017504642A5 (enExample) | ||
| JP2010529203A5 (enExample) | ||
| JP2016509047A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| EA025252B1 (ru) | Способы и соединения для лечения вирусных инфекций paramyxoviridae | |
| JP2013532652A5 (enExample) | ||
| JP2018535963A5 (enExample) | ||
| RU2009126745A (ru) | Производные сульфонилфенил-2н-{1,2,4}оксадиазол-5-она, способы их получения и их применение в качестве фармацевтических средств | |
| JP2016506962A5 (enExample) | ||
| JP2009535307A5 (enExample) | ||
| JP2005523922A5 (enExample) | ||
| JP2010501584A5 (enExample) | ||
| JP2010524932A5 (enExample) | ||
| JP2014510774A5 (enExample) | ||
| JP2017526677A5 (enExample) | ||
| JP2012506872A5 (enExample) |